AstraZeneca halts GBP£200 million investment in Cambridge research site

AstraZeneca logo on side of Cambridge Discovery Centre (DISC)

AstraZeneca, Britain's largest company by market capitalisation, has paused its planned GBP£200 million investment in its Cambridge research site, marking the latest in a series of pharmaceutical industry retreats from the UK.

The company confirmed the decision on Friday, with a spokesperson stating, "We constantly reassess the investment needs of our company and can confirm our expansion in Cambridge is paused."

The now-stalled Cambridge project had been expected to create approximately 1,000 jobs and was part of a larger GBP£650 million investment package in the UK that was originally announced in March 2024. This follows AstraZeneca's January decision to scrap plans for a GBP£450 million vaccine manufacturing facility in Speke, Merseyside, which the company attributed to a reduction in government support after months of negotiations.

AstraZeneca's retreat comes during a week of significant pharmaceutical industry pullbacks from Britain. US drugmaker Merck & Co announced it was abandoning a new research centre in London that was already under construction and due for completion by 2027, citing the UK's challenging business environment. Additionally, Eli Lilly has put on hold its planned London gateway lab, an incubator space for new drugs that was part of a GBP£279 million investment.

The pharmaceutical industry has long argued that the UK needs to increase spending on new medicines to bring NHS expenditure on medications more in line with other countries. These recent decisions by major pharmaceutical companies raise concerns about Britain's competitiveness in the life sciences sector.

In stark contrast to its UK retreat, AstraZeneca recently unveiled plans to invest US$50 billion (approximately GBP£37 billion) in the United States by 2030. This US initiative was proposed in July, as President Donald Trump threatened tariffs on medicines imported to the country. The threat of pharmaceutical tariffs has prompted several other drugmakers – including Johnson & Johnson, Eli Lilly, Novartis, and Roche – to make significant US investment pledges.

The decision represents a significant blow to Britain's ambitions as a global life sciences hub, particularly as Cambridge has been one of the country's leading centres for pharmaceutical research and development.

Source:

Exclusive: AstraZeneca pauses $270 million investment in Britain [Accessed September 16, 2025] https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-pauses-270-million-investment-britain-2025-09-12/